Biogen Inc. (BIIB)

$157.93

+1.93

(+1.24%)▲

Market is closed - opens 8 PM, 22 Nov 2024

Performance

  • $154.89
    $159.09
    $157.93
    downward going graph

    1.93%

    Downside

    Day's Volatility :2.64%

    Upside

    0.73%

    downward going graph
  • $155.28
    $268.30
    $157.93
    downward going graph

    1.68%

    Downside

    52 Weeks Volatility :42.12%

    Upside

    41.14%

    downward going graph

Returns

PeriodBiogen Inc.Sector (Health Care)Index (NASDAQ Composite)
3 Months
-24.34%
-7.6%
5.8%
6 Months
-31.49%
-2.3%
12.7%
1 Year
-32.05%
10.1%
33.6%
3 Years
-38.15%
7.5%
18.1%

Highlights

Market Capitalization
22.7B
Book Value
$112.28
Earnings Per Share (EPS)
11.07
PE Ratio
14.09
PEG Ratio
6.24
Wall Street Target Price
251.697
Profit Margin
16.81%
Operating Margin TTM
20.74%
Return On Assets TTM
4.99%
Return On Equity TTM
10.47%
Revenue TTM
9.6B
Revenue Per Share TTM
66.12
Quarterly Revenue Growth YOY
-2.5%
Gross Profit TTM
7.9B
EBITDA
2.9B
Diluted Eps TTM
11.07
Quarterly Earnings Growth YOY
-0.02
EPS Estimate Current Year
16.41
EPS Estimate Next Year
16.67
EPS Estimate Current Quarter
3.79
EPS Estimate Next Quarter
3.45

Analyst Recommendation

Buy
    71%Buy
    28%Hold
    0
    0%Sell
Based on 42 Wall street analysts offering stock ratings for Biogen Inc.(by analysts ranked 0 to 5 stars)
Based on 42 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
30
30
32
Hold
12
12
10
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 59.37%

Current $157.93
Target $251.70

Company Financials

FY18Y/Y Change
Revenue
13.5B
↑ 9.61%
Net Income
4.4B
↑ 74.5%
Net Profit Margin
32.93%
↑ 12.24%
FY19Y/Y Change
Revenue
14.4B
↑ 6.88%
Net Income
5.9B
↑ 32.9%
Net Profit Margin
40.96%
↑ 8.03%
FY20Y/Y Change
Revenue
13.4B
↓ 6.49%
Net Income
4.0B
↓ 32.06%
Net Profit Margin
29.76%
↓ 11.2%
FY21Y/Y Change
Revenue
11.0B
↓ 18.32%
Net Income
1.6B
↓ 61.1%
Net Profit Margin
14.17%
↓ 15.59%
FY22Y/Y Change
Revenue
10.2B
↓ 7.36%
Net Income
3.0B
↑ 95.8%
Net Profit Margin
29.95%
↑ 15.78%
FY23Y/Y Change
Revenue
9.8B
↓ 3.32%
Net Income
1.2B
↓ 61.89%
Net Profit Margin
11.81%
↓ 18.14%
Q2 FY23Q/Q Change
Revenue
2.5B
↓ 0.28%
Net Income
591.6M
↑ 52.51%
Net Profit Margin
24.09%
↑ 8.34%
Q3 FY23Q/Q Change
Revenue
2.5B
↑ 3.03%
Net Income
-68.1M
↓ 111.51%
Net Profit Margin
-2.69%
↓ 26.78%
Q4 FY23Q/Q Change
Revenue
2.4B
↓ 5.69%
Net Income
249.7M
↓ 466.67%
Net Profit Margin
10.46%
↑ 13.15%
Q1 FY24Q/Q Change
Revenue
2.2B
↓ 7.79%
Net Income
393.4M
↑ 57.55%
Net Profit Margin
17.88%
↑ 7.42%
Q2 FY24Q/Q Change
Revenue
2.4B
↑ 6.94%
Net Income
583.6M
↑ 48.35%
Net Profit Margin
24.8%
↑ 6.92%
Q3 FY24Q/Q Change
Revenue
2.5B
↑ 4.79%
Net Income
388.5M
↓ 33.43%
Net Profit Margin
15.76%
↓ 9.04%
FY18Y/Y Change
Total Assets
25.3B
↑ 6.92%
Total Liabilities
12.3B
↑ 10.88%
FY19Y/Y Change
Total Assets
27.2B
↑ 7.69%
Total Liabilities
13.9B
↑ 13.36%
FY20Y/Y Change
Total Assets
24.6B
↓ 9.6%
Total Liabilities
13.9B
↑ 0.27%
FY21Y/Y Change
Total Assets
23.9B
↓ 3.01%
Total Liabilities
12.9B
↓ 7.29%
FY22Y/Y Change
Total Assets
24.6B
↑ 2.83%
Total Liabilities
11.2B
↓ 13.56%
FY23Y/Y Change
Total Assets
26.8B
↑ 9.33%
Total Liabilities
12.0B
↑ 7.88%
Q2 FY23Q/Q Change
Total Assets
25.2B
↑ 2.27%
Total Liabilities
10.7B
↓ 1.06%
Q3 FY23Q/Q Change
Total Assets
28.2B
↑ 12.07%
Total Liabilities
13.7B
↑ 28.21%
Q4 FY23Q/Q Change
Total Assets
26.8B
↓ 4.78%
Total Liabilities
12.0B
↓ 12.16%
Q1 FY24Q/Q Change
Total Assets
26.6B
↓ 1.03%
Total Liabilities
11.4B
↓ 5.73%
Q2 FY24Q/Q Change
Total Assets
26.8B
↑ 0.89%
Total Liabilities
10.9B
↓ 3.87%
Q3 FY24Q/Q Change
Total Assets
28.3B
↑ 5.63%
Total Liabilities
12.0B
↑ 9.52%
FY18Y/Y Change
Operating Cash Flow
6.2B
↑ 35.96%
Investing Cash Flow
-2.0B
↓ 30.94%
Financing Cash Flow
-4.5B
↑ 87.9%
FY19Y/Y Change
Operating Cash Flow
7.1B
↑ 14.4%
Investing Cash Flow
470.5M
↓ 122.99%
Financing Cash Flow
-5.9B
↑ 31.05%
FY20Y/Y Change
Operating Cash Flow
4.2B
↓ 40.25%
Investing Cash Flow
-608.6M
↓ 229.35%
Financing Cash Flow
-5.3B
↓ 10.03%
FY21Y/Y Change
Operating Cash Flow
3.6B
↓ 13.95%
Investing Cash Flow
-563.7M
↓ 7.38%
Financing Cash Flow
-2.1B
↓ 60.43%
FY22Y/Y Change
Operating Cash Flow
1.4B
↓ 61.97%
Investing Cash Flow
1.6B
↓ 379.69%
Financing Cash Flow
-1.8B
↓ 15.65%
Q2 FY23Q/Q Change
Operating Cash Flow
487.0M
↑ 6.96%
Investing Cash Flow
-753.5M
↓ 20.93%
Financing Cash Flow
-9.8M
↓ 77.42%

Technicals Summary

Sell

Neutral

Buy

Biogen Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Biogen Inc.
Biogen Inc.
-15.52%
-31.49%
-32.05%
-38.15%
-45.92%
Eli Lilly And Company
Eli Lilly And Company
-16.85%
-6.2%
27.14%
189.28%
556.57%
Johnson & Johnson
Johnson & Johnson
-5.97%
1.24%
1.32%
-4.13%
12.22%
Merck & Co. Inc.
Merck & Co. Inc.
-8.37%
-25.48%
-4.67%
19.35%
14.02%
Novo Nordisk A/s
Novo Nordisk A/s
-10.28%
-22.11%
2.42%
89.28%
289.6%
Abbvie Inc
Abbvie Inc
-10.07%
2.96%
20.93%
45.06%
93.9%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Biogen Inc.
Biogen Inc.
14.28
14.09
6.24
16.41
0.1
0.05
NA
112.28
Eli Lilly And Company
Eli Lilly And Company
78.72
78.72
0.69
13.16
0.65
0.14
0.01
15.83
Johnson & Johnson
Johnson & Johnson
25.45
25.45
0.92
9.96
0.21
0.08
0.03
29.14
Merck & Co. Inc.
Merck & Co. Inc.
20.2
20.2
0.07
7.74
0.28
0.11
0.03
17.58
Novo Nordisk A/s
Novo Nordisk A/s
34.03
34.03
1.53
22.7
0.89
0.21
0.01
27.07
Abbvie Inc
Abbvie Inc
57.94
58.04
0.4
10.94
0.56
0.08
0.04
3.41
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Biogen Inc.
Biogen Inc.
Buy
$23.0B
-45.92%
14.28
16.81%
Eli Lilly And Company
Eli Lilly And Company
Buy
$692.7B
556.57%
78.72
20.48%
Johnson & Johnson
Johnson & Johnson
Buy
$370.8B
12.22%
25.45
16.74%
Merck & Co. Inc.
Merck & Co. Inc.
Buy
$244.3B
14.02%
20.2
19.23%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$472.8B
289.6%
34.03
35.01%
Abbvie Inc
Abbvie Inc
Buy
$293.8B
93.9%
57.94
9.22%

Insights on Biogen Inc.

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 2.20B → 2.46B (in $), with an average increase of 5.5% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 583.6M → 388.5M (in $), with an average decrease of 33.4% per quarter

  • Vs LLY

    In the last 1 year, Eli Lilly And Company has given 27.1% return, outperforming this stock by 59.1%

  • Vs LLY

    In the last 3 years, Eli Lilly And Company has given 189.0% return, outperforming this stock by 228.3%

Institutional Holdings

  • Vanguard Group Inc

    11.45%

  • PRIMECAP Management Company

    11.20%

  • BlackRock Inc

    9.98%

  • State Street Corp

    4.87%

  • Wellington Management Company LLP

    3.55%

  • JPMorgan Chase & Co

    3.24%

Company Information

through cutting-edge science and medicine, biogen discovers, develops and delivers innovative therapies worldwide for people living with serious neurological and neurodegenerative diseases. founded in 1978, biogen is a pioneer in biotechnology and today the company has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first and only approved treatment for spinal muscular atrophy, and is at the forefront of neurology research for conditions including alzheimer’s disease, parkinson’s disease and amyotrophic lateral sclerosis. biogen also manufactures and commercializes biosimilars of advanced biologics. with approximately 7000 people worldwide, we are truly a global organization, headquartered in cambridge, massachusetts, which is also home to our research operations. our international headquarters are based in zug, switzerland and we have world-class manufacturing facilities in north carolina and denmark. we offer therapies globally through direct affili

Organization
Biogen Inc.
Employees
7570
CEO
Mr. Christopher A. Viehbacher
Industry
Health Technology

FAQs